Table of Contents
ISRN Molecular Biology
Volume 2012 (2012), Article ID 381428, 28 pages
http://dx.doi.org/10.5402/2012/381428
Review Article

The Dual Role of TGF in Human Cancer: From Tumor Suppression to Cancer Metastasis

Division of Medical Oncology, Department of Medicine, Royal Victoria Hospital, McGill University Health Center, Montreal, QC, Canada H3A 1A1

Received 25 September 2012; Accepted 12 October 2012

Academic Editors: D. Christophe and S. N. Richter

Copyright © 2012 Jean-Jacques Lebrun. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. N. Fabricant and C. J. Todaro, “Nerve growth factor and malignant melanomas,” New England Journal of Medicine, vol. 298, no. 7, p. 402, 1978. View at Publisher · View at Google Scholar
  2. J. E. De Larco and G. J. Todaro, “Growth factors from murine sarcoma virus-transformed cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 8, pp. 4001–4005, 1978. View at Google Scholar · View at Scopus
  3. A. B. Roberts, M. A. Anzano, C. A. Meyers et al., “Purification and properties of a type β transforming growth factor from bovine kidney,” Biochemistry, vol. 22, no. 25, pp. 5692–5698, 1983. View at Google Scholar · View at Scopus
  4. J. Massagué, “TGFβ in cancer,” Cell, vol. 134, no. 2, pp. 215–230, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-J. Lebrun, “Activin, TGF-β and menin in pituitary tumorigenesis,” Advances in Experimental Medicine and Biology, vol. 668, pp. 69–78, 2009. View at Google Scholar · View at Scopus
  6. L. Humbert, J. C. Neel, and J.-J. Lebrun, “Targeting TGF-beta signaling in human cancer therapy,” Trends in Cell & Molecular Biology, vol. 5, pp. 69–107, 2010. View at Google Scholar
  7. J.-J. Lebrun, Y. Chen, and W. W. Vale, “Receptor serine kinases and signaling by activins and inhibins,” in Activin and Follistatin, Regulatory Functions in System and Cell Biology, pp. 1–20, Serono Symposia Publication, Springer, New York, NY, USA, 1997. View at Google Scholar
  8. J. Massagué, “TGF-β signal transduction,” Annual Review of Biochemistry, vol. 67, pp. 753–791, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Derynck, R. J. Akhurst, and A. Balmain, “TGF-β signaling in tumor suppression and cancer progression,” Nature Genetics, vol. 29, no. 2, pp. 117–129, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Chin, G. M. Boyle, P. G. Parsons, and W. B. Coman, “What is transforming growth factor-beta (TGF-β)?” British Journal of Plastic Surgery, vol. 57, no. 3, pp. 215–221, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. P. D. Sun and D. R. Davies, “The cystine-knot growth-factor superfamily,” Annual Review of Biophysics and Biomolecular Structure, vol. 24, pp. 269–291, 1995. View at Google Scholar · View at Scopus
  12. K. Miyazono, H. Ichijo, and C. H. Heldin, “Transforming growth factor-β: latent forms, binding proteins and receptors,” Growth Factors, vol. 8, no. 1, pp. 11–22, 1993. View at Google Scholar · View at Scopus
  13. K. Koli, J. Saharinen, M. Hyytiäinen, C. Penttinen, and J. Keski-Oja, “Latency, activation, and binding proteins of TGF-β,” Microscopy Research and Technique, vol. 52, no. 4, pp. 354–362, 2001. View at Publisher · View at Google Scholar
  14. N. Khalil, “TGF-β: from latent to active,” Microbes and Infection, vol. 1, no. 15, pp. 1255–1263, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Massague, M. P. Czech, K. Iwata, J. E. DeLarco, and G. J. Todaro, “Affinity labeling of a transforming growth factor receptor that does not interact with epidermal growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 22 I, pp. 6822–6826, 1982. View at Google Scholar · View at Scopus
  16. J. Massague and B. Like, “Cellular receptors for type β transforming growth factor. Ligand binding and affinity labeling in human and rodent cell lines,” Journal of Biological Chemistry, vol. 260, no. 5, pp. 2636–2645, 1985. View at Google Scholar · View at Scopus
  17. J. Massague, “The transforming growth factor-β family,” Annual Review of Cell Biology, vol. 6, pp. 597–641, 1990. View at Google Scholar · View at Scopus
  18. Y. Shi and J. Massagué, “Mechanisms of TGF-β signaling from cell membrane to the nucleus,” Cell, vol. 113, no. 6, pp. 685–700, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Massagué, S. W. Blain, and R. S. Lo, “TGFβ signaling in growth control, cancer, and heritable disorders,” Cell, vol. 103, no. 2, pp. 295–309, 2000. View at Google Scholar · View at Scopus
  20. L. M. Wakefield and A. B. Roberts, “TGF-β signaling: positive and negative effects on tumorigenesis,” Current Opinion in Genetics and Development, vol. 12, no. 1, pp. 22–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Xu, S. Lamouille, and R. Derynck, “TGF-β-induced epithelial to mesenchymal transition,” Cell Research, vol. 19, no. 2, pp. 156–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. J. P. Their, “Epithelial-mesenchymal transitions in tumor progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002. View at Publisher · View at Google Scholar
  23. J. M. Yingling, K. L. Blanchard, and J. S. Sawyer, “Development of TGF-β signalling inhibitors for cancer therapy,” Nature Reviews Drug Discovery, vol. 3, no. 12, pp. 1011–1022, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. P. M. Siegel and J. Massagué, “Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer,” Nature Reviews Cancer, vol. 3, no. 11, pp. 807–821, 2003. View at Publisher · View at Google Scholar
  25. N. Dumont and C. L. Arteaga, “Targeting the TGFβ signaling network in human neoplasia,” Cancer Cell, vol. 3, no. 6, pp. 531–536, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. S. M. Gorsch, V. A. Memoli, T. A. Stukel, L. I. Gold, and B. A. Arrick, “Immunohistochemical staining for transforming growth factor β1 associates with disease progression in human breast cancer,” Cancer Research, vol. 52, no. 24, pp. 6949–6952, 1992. View at Google Scholar · View at Scopus
  27. J.-J. Lebrun and W. W. Vale, “Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation,” Molecular and Cellular Biology, vol. 17, no. 3, pp. 1682–1691, 1997. View at Google Scholar · View at Scopus
  28. J. Massagué and Y. G. Chen, “Controlling TGF-β signaling,” Genes and Development, vol. 14, no. 6, pp. 627–644, 2000. View at Google Scholar · View at Scopus
  29. A. Mehra and J. L. Wrana, “TGF-β and the Smad signal transduction pathway,” Biochemistry and Cell Biology, vol. 80, no. 5, pp. 605–622, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Moustakas and C. H. Heldin, “Non-Smad TGF-β signals,” Journal of Cell Science, vol. 118, no. 16, pp. 3573–3584, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Jayaraman and J. Massagué, “Distinct oligomeric states of SMAD proteins in the transforming growth factor-β pathway,” Journal of Biological Chemistry, vol. 275, no. 52, pp. 40710–40717, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. B. M. Chacko, B. Qin, J. J. Correia, S. S. Lam, M. P. De Caestecker, and K. Lin, “The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization,” Nature Structural Biology, vol. 8, no. 3, pp. 248–253, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. B. M. Chacko, B. Y. Qin, A. Tiwari et al., “Structural basis of heteromeric Smad protein assembly in TGF-β signaling,” Molecular Cell, vol. 15, no. 5, pp. 813–823, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. J.-J. Lebrun, K. Takabe, Y. Chen, and W. Vale, “Roles of pathway-specific and inhibitory Smads in activin receptor signaling,” Molecular Endocrinology, vol. 13, no. 1, pp. 15–23, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Xu, Y. G. Chen, and J. Massagué, “The nuclear import function of Smad2 is masked by SARA and unmasked by TGFβ-dependent phosphorylation,” Nature Cell Biology, vol. 2, no. 8, pp. 559–562, 2000. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Reguly and J. L. Wrana, “In or out? The dynamics of Smad nucleocytoplasmic shuttling,” Trends in Cell Biology, vol. 13, no. 5, pp. 216–220, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Xu and J. Massagué, “Nucleocytoplasmic shuttling of signal transducers,” Nature Reviews Molecular Cell Biology, vol. 5, no. 3, pp. 209–219, 2004. View at Publisher · View at Google Scholar · View at Scopus
  38. Y. Shi, Y. F. Wang, L. Jayaraman, H. Yang, J. Massagué, and N. P. Pavletich, “Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-β signaling,” Cell, vol. 94, no. 5, pp. 585–594, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Massagué and D. Wotton, “Transcriptional control by the TGF-β/Smad signaling system,” EMBO Journal, vol. 19, no. 8, pp. 1745–1754, 2000. View at Google Scholar · View at Scopus
  40. X. Chen, E. Weisberg, V. Fridmacher, M. Watanabe, G. Naco, and M. Whitman, “Smad4 and FAST-1 in the assembly of activin-responsive factor,” Nature, vol. 389, no. 6646, pp. 85–89, 1997. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Hata, J. Seoane, G. Lagna, E. Montalvo, A. Hemmati-Brivanlou, and J. Massagué, “OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP- Smad and Olf signaling pathways,” Cell, vol. 100, no. 2, pp. 229–240, 2000. View at Google Scholar · View at Scopus
  42. X. H. Feng and R. Derynck, “Specificity and versatility in TGF-β signaling through smads,” Annual Review of Cell and Developmental Biology, vol. 21, pp. 659–693, 2005. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Massagué, J. Seoane, and D. Wotton, “Smad transcription factors,” Genes and Development, vol. 19, no. 23, pp. 2783–2810, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. V. Bakin, C. Rinehart, A. K. Tomlinson, and C. L. Arteaga, “p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiation and cell migration,” Journal of Cell Science, vol. 115, no. 15, pp. 3193–3206, 2002. View at Google Scholar · View at Scopus
  45. Z. Yan, S. Winawer, and E. Friedman, “Two different signal transduction pathways can be activated by transforming growth factor β1 in epithelial cells,” Journal of Biological Chemistry, vol. 269, no. 18, pp. 13231–13237, 1994. View at Google Scholar · View at Scopus
  46. H. Hanafusa, J. Ninomiya-Tsuji, N. Masuyama et al., “Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-β-induced gene expression,” Journal of Biological Chemistry, vol. 274, no. 38, pp. 27161–27167, 1999. View at Publisher · View at Google Scholar · View at Scopus
  47. E. Cocolakis, S. Lemay, S. Ali, and J.-J. Lebrun, “The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin,” Journal of Biological Chemistry, vol. 276, no. 21, pp. 18430–18436, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Lacerte, J. Korah, M. Roy, X. J. Yang, S. Lemay, and J.-J. Lebrun, “Transforming growth factor-β inhibits telomerase through SMAD3 and E2F transcription factors,” Cellular Signalling, vol. 20, no. 1, pp. 50–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. C. De Guise, A. Lacerte, S. Rafiei et al., “Activin inhibits the human Pit-1 gene promoter through the p38 kinase pathway in a smad-independent manner,” Endocrinology, vol. 147, no. 9, pp. 4351–4362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Davies, M. Robinson, E. Smith, S. Huntley, S. Prime, and I. Paterson, “Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-β1 involves MAPK, Smad and AP-1 signalling pathways,” Journal of Cellular Biochemistry, vol. 95, no. 5, pp. 918–931, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. M. K. Lee, C. Pardoux, M. C. Hall et al., “TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcA,” EMBO Journal, vol. 26, no. 17, pp. 3957–3967, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Edlund, M. Landström, C. H. Heldin, and P. Aspenström, “Transforming growth factor-β-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA,” Molecular Biology of the Cell, vol. 13, no. 3, pp. 902–914, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. N. A. Bhowmick, M. Ghiassi, A. Bakin et al., “Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism,” Molecular Biology of the Cell, vol. 12, no. 1, pp. 27–36, 2001. View at Google Scholar · View at Scopus
  54. R. H. Chen, Y. H. Su, R. L. C. Chuang, and T. Y. Chang, “Suppression of transforming growth factor-β-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway,” Oncogene, vol. 17, no. 15, pp. 1959–1968, 1998. View at Google Scholar · View at Scopus
  55. P. Péron, M. Rahmani, Y. Zagar, A. M. Durand-Schneider, B. Lardeux, and D. Bernuau, “Potentiation of Smad transactivation by Jun proteins during a combined treatment with epidermal growth factor and transforming growth factor-β in rat hepatocytes: role of phosphatidylinositol 3-kinase-induced AP-1 activation,” Journal of Biological Chemistry, vol. 276, no. 13, pp. 10524–10531, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Lamouille and R. Derynck, “Cell size and invasion in TGF-β-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway,” Journal of Cell Biology, vol. 178, no. 3, pp. 437–451, 2007. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Hayashi, S. Abdollah, Y. Qiu et al., “The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling,” Cell, vol. 89, no. 7, pp. 1165–1173, 1997. View at Google Scholar · View at Scopus
  58. A. Nakao, M. Afrakhte, A. Morén et al., “Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling,” Nature, vol. 389, no. 6651, pp. 631–635, 1997. View at Publisher · View at Google Scholar
  59. W. Shi, C. Sun, B. He et al., “GADD34-PP1c recruited by Smad7 dephosphorylates TGFβ type I receptor,” Journal of Cell Biology, vol. 164, no. 2, pp. 291–300, 2004. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Kavsak, R. K. Rasmussen, C. G. Causing et al., “Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGFβ receptor for degradation,” Molecular Cell, vol. 6, no. 6, pp. 1365–1375, 2000. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Suzuki, G. Murakami, M. Fukuchi et al., “Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane,” Journal of Biological Chemistry, vol. 277, no. 42, pp. 39919–39925, 2002. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Tajima, K. Goto, M. Yoshida et al., “Chromosomal region maintenance 1 (CRM1)-dependent nuclear export of Smad ubiquitin regulatory factor 1 (Smurf1) is essential for negative regulation of transforming growth factor-β signaling by Smad7,” Journal of Biological Chemistry, vol. 278, no. 12, pp. 10716–10721, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. G. M. Di Guglielmo, C. Le Roy, A. F. Goodfellow, and J. L. Wrana, “Distinct endocytic pathways regulate TGF-β receptor signalling and turnover,” Nature Cell Biology, vol. 5, no. 5, pp. 410–421, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. W. Chen, K. C. Kirkbride, T. How et al., “β-arrestin 2 mediates endocytosis of type III TGF-β receptor and down-regulation of its signaling,” Science, vol. 301, no. 5638, pp. 1394–1397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. D. Yao, M. Ehrlich, Y. I. Henis, and E. B. Leof, “Transforming growth factor-β receptors interact with AP2 by direct binding to β2 subunit,” Molecular Biology of the Cell, vol. 13, no. 11, pp. 4001–4012, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. R. S. Lo and J. Massague, “Ubiquitin-dependent degradation of TGF-beta-activated smad2,” Nature Cell Biology, vol. 1, pp. 472–478, 1999. View at Publisher · View at Google Scholar
  67. X. Lin, X. Duan, Y. Y. Liang et al., “PPM1A functions as a smad phosphatase to terminate TGFβ signaling,” Cell, vol. 125, no. 5, pp. 915–928, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. L. Xu, Y. Kang, S. Çöl, and J. Massagué, “Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFβ signaling complexes in the cytoplasm and nucleus,” Molecular Cell, vol. 10, no. 2, pp. 271–282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. G. J. Inman, F. J. Nicolás, and C. S. Hill, “Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-β receptor activity,” Molecular Cell, vol. 10, no. 2, pp. 283–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Kretzschmar, J. Doody, and J. Massagué, “Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smad1,” Nature, vol. 389, no. 6651, pp. 618–622, 1997. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Kretzschmar, J. Doody, I. Timokhina, and J. Massagué, “A mechanism of repression of TGFfβ/Smad signaling by oncogenic Ras,” Genes and Development, vol. 13, no. 7, pp. 804–816, 1999. View at Google Scholar · View at Scopus
  72. H. Nagata, E. Hatano, M. Tada et al., “Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor-suppression in rat hepatocellular carcinoma,” Hepatology, vol. 49, no. 6, pp. 1944–1953, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Kretzschmar, F. Liu, A. Hata, J. Doody, and J. Massagué, “The TGF-β family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase,” Genes and Development, vol. 11, no. 8, pp. 984–995, 1997. View at Google Scholar · View at Scopus
  74. S. J. Wicks, L. Stephen, N. Abdel-Wahab, R. M. Mason, and A. Chantry, “Inactivation of Smad-transforming growth factor β signaling by Ca2+-calmodulin-dependent protein kinase II,” Molecular and Cellular Biology, vol. 20, no. 21, pp. 8103–8111, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. I. Matsuura, N. G. Denissova, G. Wang, D. He, J. Long, and F. Liu, “Cyclin-dependent kinases regulate the antiproliferative function of Smads,” Nature, vol. 430, no. 6996, pp. 226–231, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. D. S. Waddell, N. T. Liberati, X. Guo, J. P. Frederick, and Y. F. Wang, “Casein kinase Iε plays a functional role in the transforming growth factor-β signaling pathway,” Journal of Biological Chemistry, vol. 279, no. 28, pp. 29236–29246, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. I. Yakymovych, U. Engström, S. Grimsby, C. H. Heldin, and S. Souchelnytskyi, “Inhibition of transforming growth factor-β signaling by low molecular weight compounds interfering with ATP- or substrate-binding sites of the TGFβ type I receptor kinase,” Biochemistry, vol. 41, no. 36, pp. 11000–11007, 2002. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Ho, E. Cocolakis, V. M. Dumas, B. I. Posner, S. A. Laporte, and J.-J. Lebrun, “The G protein-coupled receptor kinase-2 is a TGFβ-inducible antagonist of TGFβ signal transduction,” EMBO Journal, vol. 24, no. 18, pp. 3247–3258, 2005. View at Publisher · View at Google Scholar
  79. J. Guo, H. Chen, J. Ho et al., “TGFβ-induced GRK2 expression attenuates AngII-regulated vascular smooth muscle cell proliferation and migration,” Cellular Signalling, vol. 21, no. 6, pp. 899–905, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. J. Ho, H. Chen, and J.-J. Lebrun, “Novel dominant negative Smad antagonists to TGFβ signaling,” Cellular Signalling, vol. 19, no. 7, pp. 1565–1574, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Sun, G. Wu, J. K. V. Willson et al., “Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells,” Journal of Biological Chemistry, vol. 269, no. 42, pp. 26449–26455, 1994. View at Google Scholar · View at Scopus
  82. J. Wang, L. Sun, L. Myeroff et al., “Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error- positive colon carcinoma cells,” Journal of Biological Chemistry, vol. 270, no. 37, pp. 22044–22049, 1995. View at Publisher · View at Google Scholar · View at Scopus
  83. C. Go, P. Li, and X. J. Wang, “Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis,” Cancer Research, vol. 59, no. 12, pp. 2861–2868, 1999. View at Google Scholar · View at Scopus
  84. E. P. Böttinger, J. L. Jakubczak, D. C. Haines, K. Bagnall, and L. M. Wakefield, “Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]- anthracene,” Cancer Research, vol. 57, no. 24, pp. 5564–5570, 1997. View at Google Scholar · View at Scopus
  85. S. J. Kim, Y. H. Im, S. D. Markowitz, and Y. J. Bang, “Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis,” Cytokine and Growth Factor Reviews, vol. 11, no. 1-2, pp. 159–168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  86. H. L. Moses, E. Y. Yang, and J. A. Pietenpol, “TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights,” Cell, vol. 63, no. 2, pp. 245–247, 1990. View at Publisher · View at Google Scholar · View at Scopus
  87. J. M. Li, M. A. Nichols, S. Chandrasekharan, Y. Xiong, and X. F. Wang, “Transforming growth factor β activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site,” Journal of Biological Chemistry, vol. 270, no. 45, pp. 26750–26753, 1995. View at Publisher · View at Google Scholar · View at Scopus
  88. M. B. Datto, Y. Li, J. F. Panus, D. J. Howe, Y. Xiong, and X. F. Wang, “Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 12, pp. 5545–5549, 1995. View at Publisher · View at Google Scholar · View at Scopus
  89. J. Seoane, H. V. Le, L. Shen, S. A. Anderson, and J. Massagué, “Integration of smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation,” Cell, vol. 117, no. 2, pp. 211–223, 2004. View at Publisher · View at Google Scholar · View at Scopus
  90. K. Pardali, A. Kurisaki, A. Morén, P. Ten Dijke, D. Kardassis, and A. Moustakas, “Role of Smad proteins and transcription factor Sp1 in p21Waf1/Cip1 regulation by transforming growth factor-β,” Journal of Biological Chemistry, vol. 275, no. 38, pp. 29244–29256, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Ho, C. De Guise, C. Kim, S. Lemay, X. F. Wang, and J.-J. Lebrun, “Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and Sp1,” Cellular Signalling, vol. 16, no. 6, pp. 693–701, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. I. Reynisdottir, K. Polyak, A. Iavarone, and J. Massague, “Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β,” Genes and Development, vol. 9, no. 15, pp. 1831–1845, 1995. View at Google Scholar · View at Scopus
  93. C. Sandhu, J. Garbe, N. Bhattacharya et al., “Transforming growth factor β stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells,” Molecular and Cellular Biology, vol. 17, no. 5, pp. 2458–2467, 1997. View at Google Scholar · View at Scopus
  94. R. J. Coffey, C. C. Bascom, N. J. Sipes, R. Graves-Deal, B. E. Weissman, and H. L. Moses, “Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor β,” Molecular and Cellular Biology, vol. 8, no. 8, pp. 3088–3093, 1988. View at Google Scholar · View at Scopus
  95. Y. Kang, C. R. Chen, and J. Massagué, “A self-enabling TGFβ response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells,” Molecular Cell, vol. 11, no. 4, pp. 915–926, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Lasorella, M. Noseda, M. Beyna, and A. Iavarone, “Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins,” Nature, vol. 407, no. 6804, pp. 592–598, 2000. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Kowanetz, U. Valcourt, R. Bergström, C. H. Heldin, and A. Moustakas, “Id2 and Id3 define the potency of cell proliferation and differentiation responses to transforming growth factor β and bone morphogenetic protein,” Molecular and Cellular Biology, vol. 24, no. 10, pp. 4241–4254, 2004. View at Publisher · View at Google Scholar · View at Scopus
  98. J. D. Norton, “ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis,” Journal of Cell Science, vol. 113, part 22, pp. 3897–3905, 2000. View at Google Scholar · View at Scopus
  99. C. R. Chen, Y. Kang, P. M. Siegel, and J. Massagué, “E2F4/5 and p107 as Smad cofactors linking the TGFβ receptor to c-myc repression,” Cell, vol. 110, no. 1, pp. 19–32, 2002. View at Publisher · View at Google Scholar · View at Scopus
  100. J. Seoane, C. Pouponnot, P. Staller, M. Schader, M. Eilers, and J. Massagué, “TGFβ influences myc, miz-1 and smad to control the CDK inhibitor p15INK4b,” Nature Cell Biology, vol. 3, no. 4, pp. 400–408, 2001. View at Publisher · View at Google Scholar · View at Scopus
  101. P. Staller, K. Peukert, A. Kiermaier et al., “Repression of p15INK4b expression by Myc through association with Miz-1,” Nature Cell Biology, vol. 3, no. 4, pp. 392–399, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. C.-I. J. Ma, C. Martin, Z. Ma et al., “Engulfment protein GULP is regulator of transforming growth factor-β response in ovarian cells,” Journal of Biological Chemistry, vol. 287, no. 24, pp. 20636–20651, 2012. View at Publisher · View at Google Scholar
  103. A. Iavarone and J. Massagué, “Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15,” Nature, vol. 387, no. 6631, pp. 417–422, 1997. View at Publisher · View at Google Scholar · View at Scopus
  104. H. Kaji, L. Canaff, J.-J. Lebrun, D. Goltzman, and G. N. Hendy, “Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type β signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 3837–3842, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. C. N. Hendy, H. Kaji, H. Sowa, J.-J. Lebrun, and L. Canaff, “Menin and TGF-β superfamily member signaling via the Smad pathway in pituitary, parathyroid and osteoblast,” Hormone and Metabolic Research, vol. 37, no. 6, pp. 375–379, 2005. View at Publisher · View at Google Scholar · View at Scopus
  106. N. Ben-Jonathan and R. Hnasko, “Dopamine as a prolactin (PRL) inhibitor,” Endocrine Reviews, vol. 22, no. 6, pp. 724–763, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. A. P. Heaney and S. Melmed, “Molecular targets in pituitary tumours,” Nature Reviews Cancer, vol. 4, no. 4, pp. 285–295, 2004. View at Google Scholar · View at Scopus
  108. S. L. Asa and S. Ezzat, “The cytogenesis and pathogenesis of pituitary adenomas,” Endocrine Reviews, vol. 19, no. 6, pp. 798–827, 1998. View at Google Scholar · View at Scopus
  109. S. S. Guo and M. P. Sawicki, “Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1,” Molecular Endocrinology, vol. 15, no. 10, pp. 1653–1664, 2001. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Lacerte, E. H. Lee, R. Reynaud et al., “Activin inhibits pituitary prolactin expression and cell growth through Smads, Pit-1 and menin,” Molecular Endocrinology, vol. 18, no. 6, pp. 1558–1569, 2004. View at Publisher · View at Google Scholar · View at Scopus
  111. F. A. Oberhammer, M. Pavelka, S. Sharma et al., “Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 12, pp. 5408–5412, 1992. View at Publisher · View at Google Scholar · View at Scopus
  112. N. Chaouchi, L. Arvanitakis, M. T. Auffredou, D. A. Blanchard, A. Vazquez, and S. Sharma, “Characterization of transforming growth factor-β1 induced apoptosis in normal human B cells and lymphoma B cell lines,” Oncogene, vol. 11, no. 8, pp. 1615–1622, 1995. View at Google Scholar · View at Scopus
  113. H. Valderrama-Carvajal, E. Cocolakis, A. Lacerte et al., “Activin/TGF-β induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP,” Nature Cell Biology, vol. 4, no. 12, pp. 963–969, 2002. View at Publisher · View at Google Scholar · View at Scopus
  114. K. Yanagisawa, H. Osada, A. Masuda et al., “Induction of apoptosis by Smad3 and down-regulation of Smad3 expression in response to TGF-β in human normal lung epithelial cells,” Oncogene, vol. 17, no. 13, pp. 1743–1747, 1998. View at Google Scholar · View at Scopus
  115. R. J. Rotello, R. C. Lieberman, A. F. Purchio, and L. E. Gerschenson, “Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β1 in cultured uterine epithelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 8, pp. 3412–3415, 1991. View at Google Scholar · View at Scopus
  116. N. Schuster and K. Krieglstein, “Mechanisms of TGF-β-mediated apoptosis,” Cell and Tissue Research, vol. 307, no. 1, pp. 1–14, 2002. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Perlman, W. P. Schiemann, M. W. Brooks, H. F. Lodish, and R. A. Weinberg, “TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation,” Nature Cell Biology, vol. 3, no. 8, pp. 708–714, 2001. View at Publisher · View at Google Scholar · View at Scopus
  118. C. W. Jang, C. H. Chen, C. C. Chen, J. Y. Chen, Y. H. Su, and R. H. Chen, “TGF-β induces apoptosis through Smad-mediated expression of DAP-kinase,” Nature Cell Biology, vol. 4, no. 1, pp. 51–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. I. Tachibana, M. Imoto, P. N. Adjei et al., “Overexpression of the TGFβ-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells,” Journal of Clinical Investigation, vol. 99, no. 10, pp. 2365–2374, 1997. View at Google Scholar · View at Scopus
  120. S. Larisch, Y. Yi, R. Lotan et al., “A novel mitochondrial septin-like protein, ARTS, mediates apoptosis dependent on its P-loop motif,” Nature Cell Biology, vol. 2, no. 12, pp. 915–921, 2000. View at Publisher · View at Google Scholar · View at Scopus
  121. A. Atfi, M. Buisine, A. Mazars, and C. Gespach, “Induction of apoptosis by DPC4, a transcriptional factor regulated by transforming growth factor-β through stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) signaling pathway,” Journal of Biological Chemistry, vol. 272, no. 40, pp. 24731–24734, 1997. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Yamamura, X. Hua, S. Bergelson, and H. F. Lodish, “Critical role of Smads and AP-1 complex in transforming growth factor-β-dependent apoptosis,” Journal of Biological Chemistry, vol. 275, no. 46, pp. 36295–36302, 2000. View at Publisher · View at Google Scholar · View at Scopus
  123. M. Ohgushi, S. Kuroki, H. Fukamachi et al., “Transforming growth factor β-dependent sequential activation of Smad, Bim, and caspase-9 mediates physiological apoptosis in gastric epithelial cells,” Molecular and Cellular Biology, vol. 25, no. 22, pp. 10017–10028, 2005. View at Publisher · View at Google Scholar · View at Scopus
  124. G. M. Wildey, S. Patil, and P. H. Howe, “Smad3 potentiates transforming growth factor β (TGFβ)-induced apoptosis and expression of the BH3-only protein Bim in WEHI 231 B lymphocytes,” Journal of Biological Chemistry, vol. 278, no. 20, pp. 18069–18077, 2003. View at Publisher · View at Google Scholar · View at Scopus
  125. A. Saltzman, R. Munro, G. Searfoss, C. Franks, M. Jaye, and Y. Ivashchenko, “Transforming growth factor-β-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-X(L) downregulation,” Experimental Cell Research, vol. 242, no. 1, pp. 244–254, 1998. View at Publisher · View at Google Scholar · View at Scopus
  126. J. M. Francis, C. M. Heyworth, E. Spooncer, A. Pierce, T. M. Dexter, and A. D. Whetton, “Transforming growth factor-β1 induces apoptosis independently of p53 and selectively reduces expression of Bcl-2 in multipotent hematopoietic cells,” Journal of Biological Chemistry, vol. 275, no. 50, pp. 39137–39145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  127. J. E. Chipuk, M. Bhat, A. Y. Hsing, J. Ma, and D. Danielpour, “Bcl-xL Blocks transforming growth factor-β1-induced apoptosis by inhibiting cytochrome c release and not by directly antagonizing Apaf-1-dependent caspase activation in prostate epithelial cells,” Journal of Biological Chemistry, vol. 276, no. 28, pp. 26614–26621, 2001. View at Publisher · View at Google Scholar · View at Scopus
  128. C. Kanamaru, H. Yasuda, and T. Fujita, “Involvement of Smad proteins in TGF-β and activin A-induced apoptosis and growth inhibition of liver cells,” Hepatology Research, vol. 23, no. 3, pp. 211–219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Wang, L. Yang, J. Yang et al., “Transforming growth factor β induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells,” Cancer Research, vol. 68, no. 9, pp. 3152–3160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. A. R. Conery, Y. Cao, E. A. Thompson, C. M. Townsend, T. C. Ko, and K. Luo, “Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis,” Nature Cell Biology, vol. 6, no. 4, pp. 366–372, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. I. Remy, A. Montmarquette, and S. W. Michnick, “PKB/Akt modulates TGF-β signalling through a direct interaction with Smad3,” Nature Cell Biology, vol. 6, no. 4, pp. 358–365, 2004. View at Publisher · View at Google Scholar · View at Scopus
  132. J. Yang, K. Song, T. L. Krebs, M. W. Jackson, and D. Danielpour, “Rb/E2F4 and Smad2/3 link survivin to TGF-β-induced apoptosis and tumor progression,” Oncogene, vol. 27, no. 40, pp. 5326–5338, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. J. Korah, N. Falah, A. Lacerte, and J.-J. Lebrun, “A transcriptionally active pRb-E2F1-P/CAF signaling pathway is central to TGFβ-mediated apoptosis,” Cell Death and Disease Cell Death and Disease, vol. 3, article e407, 2012. View at Publisher · View at Google Scholar
  134. J. W. Shay and W. E. Wright, “Hayflick, his limit, and cellular ageing,” Nature Reviews Molecular Cell Biology, vol. 1, no. 1, pp. 72–76, 2000. View at Google Scholar · View at Scopus
  135. S. Rama, Y. Suresh, and A. J. Rao, “Regulation of telomerase during human placental differentiation: a role for TGFβ1,” Molecular and Cellular Endocrinology, vol. 182, no. 2, pp. 233–248, 2001. View at Google Scholar · View at Scopus
  136. H. Yang, S. Kyo, M. Takatura, and L. Sun, “Autocrine transforming growth factor β suppresses telomerase activity and transcription of human telomerase reverse transcriptase in human cancer cells,” Cell Growth and Differentiation, vol. 12, no. 2, pp. 119–127, 2001. View at Google Scholar · View at Scopus
  137. G. C. Blobe, W. P. Schiemann, and H. F. Lodish, “Role of transforming growth factor β in human disease,” New England Journal of Medicine, vol. 342, no. 18, pp. 1350–1358, 2000. View at Publisher · View at Google Scholar · View at Scopus
  138. L. Levy and C. S. Hill, “Alterations in components of the TGF-β superfamily signaling pathways in human cancer,” Cytokine and Growth Factor Reviews, vol. 17, no. 1-2, pp. 41–58, 2006. View at Publisher · View at Google Scholar · View at Scopus
  139. A. Hata Phd, J. Massagué Phd, and Y. Shi Phd, “TGF-β signaling and cancer: structural and functional consequences of mutations in Smads,” Molecular Medicine Today, vol. 4, no. 6, pp. 257–262, 1998. View at Publisher · View at Google Scholar · View at Scopus
  140. T. T. Maliekal, M. L. Antony, A. Nair, R. Paulmurugan, and D. Karunagaran, “Loss of expression, and mutations of Smad 2 and Smad 4 in human cervical cancer,” Oncogene, vol. 22, no. 31, pp. 4889–4897, 2003. View at Publisher · View at Google Scholar · View at Scopus
  141. S. A. Hahn, M. Schutte, A. T. M. Shamsul Hoque et al., “DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1,” Science, vol. 271, no. 5247, pp. 350–353, 1996. View at Google Scholar · View at Scopus
  142. T. Sjöblom, S. Jones, L. D. Wood et al., “The consensus coding sequences of human breast and colorectal cancers,” Science, vol. 314, no. 5797, pp. 268–274, 2006. View at Publisher · View at Google Scholar
  143. L. A. Wolfraim, T. M. Fernandez, M. Mamura et al., “Loss of Smad3 in acute T-cell lymphoblastic leukemia,” New England Journal of Medicine, vol. 351, no. 6, pp. 552–559, 2004. View at Publisher · View at Google Scholar · View at Scopus
  144. Q. Zhu, A. R. Krakowski, E. E. Dunham et al., “Dual role of SnoN in mammalian tumorigenesis,” Molecular and Cellular Biology, vol. 27, no. 1, pp. 324–339, 2007. View at Publisher · View at Google Scholar · View at Scopus
  145. J. Kleeff, T. Ishiwata, H. Maruyama et al., “The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer,” Oncogene, vol. 18, no. 39, pp. 5363–5372, 1999. View at Publisher · View at Google Scholar · View at Scopus
  146. S. C. Dowdy, A. Mariani, M. M. Reinholz et al., “Overexpression of the TGF-β antagonist Smad7 in endometrial cancer,” Gynecologic Oncology, vol. 96, no. 2, pp. 368–373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. J. M. Cerutti, K. N. Ebina, S. E. Matsuo, L. Martins, R. M. B. Maciel, and E. T. Kimura, “Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines,” Journal of Endocrinological Investigation, vol. 26, no. 6, pp. 516–521, 2003. View at Google Scholar · View at Scopus
  148. A. Bruna, R. S. Darken, F. Rojo et al., “High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene,” Cancer Cell, vol. 11, no. 2, pp. 147–160, 2007. View at Publisher · View at Google Scholar · View at Scopus
  149. A. Hannigan, P. Smith, G. Kalna et al., “Epigenetic downregulation of human disabled homolog 2 switches TGF-β from a tumor suppressor to a tumor promoter,” Journal of Clinical Investigation, vol. 120, no. 8, pp. 2842–2857, 2010. View at Publisher · View at Google Scholar
  150. D. S. Micalizzi, K. L. Christensen, P. Jedlicka et al., “The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-β signaling,” Journal of Clinical Investigation, vol. 119, no. 9, pp. 2678–2690, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. R. J. Akhurst and R. Derynck, “TGF-β signaling in cancer—a double-edged sword,” Trends in Cell Biology, vol. 11, no. 11, pp. S44–S51, 2001. View at Publisher · View at Google Scholar · View at Scopus
  152. C. C. Compton, D. R. Byrd, J. Garcia-Aguilar, S. Kurtzman, A. Olawaiye, and M. K. Washington, Eds., AJCC Staging Manual, Springer, 7th edition, 2009.
  153. C. Arslan, K. Altundag, and O. Dizdar, “Emerging drugs in metastatic breast cancer: an update,” Expert Opinion on Emerging Drugs, vol. 16, no. 4, pp. 647–667, 2011. View at Publisher · View at Google Scholar
  154. F. Tian, S. DaCosta Byfield, W. T. Parks et al., “Smad-binding defective mutant of transforming growth factor β type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines,” Cancer Research, vol. 64, no. 13, pp. 4523–4530, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. F. Tian, S. D. Byfield, W. T. Parks et al., “Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines,” Cancer Research, vol. 63, no. 23, pp. 8284–8292, 2003. View at Google Scholar · View at Scopus
  156. H. Azuma, S. Ehata, H. Miyazaki et al., “Effect of Smad7 expression on metastasis of mouse mammary carcinoma JygMC(A) cells,” Journal of the National Cancer Institute, vol. 97, no. 23, pp. 1734–1746, 2005. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Deckers, M. Van Dinther, J. Buijs et al., “The tumor suppressor Smad4 is required for transforming growth factor β-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells,” Cancer Research, vol. 66, no. 4, pp. 2202–2209, 2006. View at Publisher · View at Google Scholar · View at Scopus
  158. Y. Kang, W. He, S. Tulley et al., “Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13909–13914, 2005. View at Publisher · View at Google Scholar
  159. R. Derynck, D. V. Goeddel, and A. Ullrich, “Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors,” Cancer Research, vol. 47, no. 3, pp. 707–712, 1987. View at Google Scholar · View at Scopus
  160. R. B. Dickson, A. Kasid, and K. K. Huff, “Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17β-estradiol or v-Ha-ras oncogene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 3, pp. 837–841, 1987. View at Google Scholar · View at Scopus
  161. B. I. Dalal, P. A. Keown, and A. H. Greenberg, “Immunocytochemical localization of secreted transforming growth factor- β1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma,” American Journal of Pathology, vol. 143, no. 2, pp. 381–389, 1993. View at Google Scholar · View at Scopus
  162. R. A. Walker, S. J. Dearing, and B. Gallacher, “Relationship of transforming growth factor β1 to extracellular matrix and stromal infiltrates in invasive breast carcinoma,” British Journal of Cancer, vol. 69, no. 6, pp. 1160–1165, 1994. View at Google Scholar · View at Scopus
  163. D. A. Thomas and J. Massagué, “TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance,” Cancer Cell, vol. 8, no. 5, pp. 369–380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  164. J. H. Kehrl, L. M. Wakefield, and A. B. Roberts, “Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth,” Journal of Experimental Medicine, vol. 163, no. 5, pp. 1037–1050, 1986. View at Google Scholar · View at Scopus
  165. F. Geissmann, P. Revy, A. Regnault et al., “TGF-β1 prevents the noncognate maturation of human dendritic Langerhans cells,” Journal of Immunology, vol. 162, no. 8, pp. 4567–4575, 1999. View at Google Scholar · View at Scopus
  166. J. J. Letterio and A. B. Roberts, “Regulation of immune responses by TGF-β,” Annual Review of Immunology, vol. 16, pp. 137–161, 1998. View at Publisher · View at Google Scholar · View at Scopus
  167. C. W. Czarniecki, H. H. Chiu, G. H. W. Wong, S. M. McCabe, and M. A. Palladino, “Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells,” Journal of Immunology, vol. 140, no. 12, pp. 4217–4223, 1988. View at Google Scholar · View at Scopus
  168. A. G. Geiser, J. J. Letterio, A. B. Kulkarni, S. Karlsson, A. B. Roberts, and M. B. Sporn, “Transforming growth factor β1 (TGF-β1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-β1 null mouse phenotype,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 21, pp. 9944–9948, 1993. View at Publisher · View at Google Scholar · View at Scopus
  169. Y. Dong, L. Tang, J. J. Letterio, and E. N. Benveniste, “The Smad3 protein is involved in TGF-β inhibition of class II transactivator and class II MHC expression,” Journal of Immunology, vol. 167, no. 1, pp. 311–319, 2001. View at Google Scholar · View at Scopus
  170. L. Gorelink and R. A. Flavell, “Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells,” Nature Medicine, vol. 7, no. 10, pp. 1118–1122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  171. A. B. Roberts, M. B. Sporn, and R. K. Assoian, “Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 12, pp. 4167–4171, 1986. View at Google Scholar · View at Scopus
  172. C. Sunderkotter, M. Goebeler, K. Schulze-Osthoff, R. Bhardwaj, and C. Sorg, “Macrophage-derived angiogenesis factors,” Pharmacology and Therapeutics, vol. 51, no. 2, pp. 195–216, 1991. View at Publisher · View at Google Scholar · View at Scopus
  173. M. S. Pepper, J. D. Vassalli, L. Orci, and R. Montesano, “Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis,” Experimental Cell Research, vol. 204, no. 2, pp. 356–363, 1993. View at Publisher · View at Google Scholar · View at Scopus
  174. M. J. Goumans, G. Valdimarsdottir, S. Itoh et al., “Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFβ/ALK5 signaling,” Molecular Cell, vol. 12, no. 4, pp. 817–828, 2003. View at Publisher · View at Google Scholar · View at Scopus
  175. M. J. Goumans, G. Valdimarsdottir, S. Itoh, A. Rosendahl, P. Sideras, and P. Ten Dijke, “Balancing the activation state of the endothelium via two distinct TGF-β type I receptors,” EMBO Journal, vol. 21, no. 7, pp. 1743–1753, 2002. View at Publisher · View at Google Scholar · View at Scopus
  176. X. Wu, J. Ma, J. D. Han, N. Wang, and Y. G. Chen, “Distinct regulation of gene expression in human endothelial cells by TGF-β and its receptors,” Microvascular Research, vol. 71, no. 1, pp. 12–19, 2006. View at Publisher · View at Google Scholar · View at Scopus
  177. T. Ota, M. Fujii, T. Sugizaki et al., “Targets of transcriptional regulation by two distinct type I receptors for transforming growth factor-β in human umbilical vein endothelial cells,” Journal of Cellular Physiology, vol. 193, no. 3, pp. 299–318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  178. M. C. Dickson, J. S. Martin, F. M. Cousins, A. B. Kulkarni, S. Karlsson, and R. J. Akhurst, “Defective haematopoiesis and vasculogenesis in transforming growth factor-β1 knock out mice,” Development, vol. 121, no. 6, pp. 1845–1854, 1995. View at Google Scholar · View at Scopus
  179. J. Larsson, M. J. Goumans, L. J. Sjöstrand et al., “Abnormal angiogenesis but intact hematopoietic potential in TGF-β type I receptor-deficient mice,” EMBO Journal, vol. 20, no. 7, pp. 1663–1673, 2001. View at Publisher · View at Google Scholar · View at Scopus
  180. M. J. Goumans, A. Zwijsen, M. A. Van Rooijen, D. Huylebroeck, B. A. J. Roelen, and C. L. Mummery, “Transforming growth factor-β signalling in extraembryonic mesoderm is required for yolk sac vasculogenesis in mice,” Development, vol. 126, no. 16, pp. 3473–3483, 1999. View at Google Scholar · View at Scopus
  181. M. Oshima, H. Oshima, and M. M. Taketo, “TGF-β receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis,” Developmental Biology, vol. 179, no. 1, pp. 297–302, 1996. View at Publisher · View at Google Scholar · View at Scopus
  182. C. B. Brown, A. S. Boyer, R. B. Runyan, and J. V. Barnett, “Requirement of type III TGF-β receptor for endocardial cell transformation in the heart,” Science, vol. 283, no. 5410, pp. 2080–2082, 1999. View at Publisher · View at Google Scholar · View at Scopus
  183. L. A. Compton, D. A. Potash, C. B. Brown, and J. V. Barnett, “Coronary vessel development is dependent on the type III transforming growth factor β receptor,” Circulation Research, vol. 101, no. 8, pp. 784–791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  184. R. J. Lechleider, J. L. Ryan, L. Garrett et al., “Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion,” Developmental Biology, vol. 240, no. 1, pp. 157–167, 2001. View at Publisher · View at Google Scholar · View at Scopus
  185. H. Chang, D. Huylebroeck, K. Verschueren, Q. Guo, M. M. Matzuk, and A. Zwijsen, “Smad5 knockout mice die at mid-gestation due to multiple embryonic and extraembryonic defects,” Development, vol. 126, no. 8, pp. 1631–1642, 1999. View at Google Scholar · View at Scopus
  186. J. S. De Jong, P. J. Van Diest, P. Van Der Valk, and J. P. A. Baak, “Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: correlations with proliferation and angiogenesis,” Journal of Pathology, vol. 184, no. 1, pp. 53–57, 1998. View at Publisher · View at Google Scholar
  187. Y. Hasegawa, S. Takanashi, Y. Kanehira, T. Tsushima, T. Imai, and K. Okumura, “Transforming growth factor-β1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma,” Cancer, vol. 91, no. 5, pp. 964–971, 2001. View at Google Scholar
  188. L. Pertovaara, A. Kaipainen, T. Mustonen et al., “Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells,” Journal of Biological Chemistry, vol. 269, no. 9, pp. 6271–6274, 1994. View at Google Scholar · View at Scopus
  189. T. Shimo, T. Nakanishi, T. Nishida et al., “Involvement of CTGF, a hypertrophic chondrocyte-specific gene product, in tumor angiogenesis,” Oncology, vol. 61, no. 4, pp. 315–322, 2001. View at Publisher · View at Google Scholar · View at Scopus
  190. H. G. Hagedorn, B. E. Bachmeier, and A. G. Nerlich, “Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review),” International Journal of Oncology, vol. 18, no. 4, pp. 669–681, 2001. View at Google Scholar · View at Scopus
  191. B. Enholm, K. Paavonen, A. Ristimäki et al., “Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia,” Oncogene, vol. 14, no. 20, pp. 2475–2483, 1997. View at Publisher · View at Google Scholar · View at Scopus
  192. O. De Wever and M. Mareel, “Role of tissue stroma in cancer cell invasion,” Journal of Pathology, vol. 200, no. 4, pp. 429–447, 2003. View at Publisher · View at Google Scholar · View at Scopus
  193. Y. Kojima, A. Acar, E. N. Eaton et al., “Autocrine TGF-β and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 46, pp. 20009–20014, 2010. View at Publisher · View at Google Scholar · View at Scopus
  194. T. M. Casey, J. Eneman, A. Crocker et al., “Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: a population study,” Breast Cancer Research and Treatment, vol. 110, no. 1, pp. 39–49, 2008. View at Publisher · View at Google Scholar · View at Scopus
  195. A. M. Sieuwerts, J. G. M. Klijn, S. C. Henzen-Logmans et al., “Urokinase-type-plasminogen-activator(UPA) production by human breast (MYO)fibroblasts in vitro: influence of transforming growth factor-β1 (TGFβ1) compared with factor(S) released by human epithelial-carcinoma cells,” International Journal of Cancer, vol. 76, no. 6, pp. 829–835, 1998. View at Google Scholar
  196. J. P. Thiery, “Epithelial-mesenchymal transitions in development and pathologies,” Current Opinion in Cell Biology, vol. 15, no. 6, pp. 740–746, 2003. View at Publisher · View at Google Scholar · View at Scopus
  197. R. Derynck and R. J. Akhurst, “Differentiation plasticity regulated by TGF-β family proteins in development and disease,” Nature Cell Biology, vol. 9, no. 9, pp. 1000–1004, 2007. View at Publisher · View at Google Scholar · View at Scopus
  198. S. Thuault, U. Valcourt, M. Petersen, G. Manfioletti, C. H. Heldin, and A. Moustakas, “Transforming growth factor-β employs HMGA2 to elicit epithelial-mesenchymal transition,” Journal of Cell Biology, vol. 174, no. 2, pp. 175–183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  199. P. J. Miettinen, R. Ebner, A. R. Lopez, and R. Derynck, “TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors,” Journal of Cell Biology, vol. 127, no. 6, pp. 2021–2036, 1994. View at Publisher · View at Google Scholar · View at Scopus
  200. M. Oft, J. Peli, C. Rudaz, H. Schwarz, H. Beug, and E. Reichmann, “TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells,” Genes and Development, vol. 10, no. 19, pp. 2462–2477, 1996. View at Google Scholar · View at Scopus
  201. G. Portella, S. A. Cumming, J. Liddell et al., “Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion,” Cell Growth and Differentiation, vol. 9, no. 5, pp. 393–404, 1998. View at Google Scholar · View at Scopus
  202. K. M. Hajra, David Y-S. Chen, and E. R. Fearon, “The SLUG zinc-finger protein represses E-cadherin in breast cancer,” Cancer Research, vol. 62, no. 6, pp. 1613–1618, 2002. View at Google Scholar · View at Scopus
  203. P. Savagner, K. M. Yamada, and J. P. Thiery, “The zinc-finger protein slug causes desmosome dissociation, an initial and necessary step for growth factor-induced epithelial-mesenchymal transition,” Journal of Cell Biology, vol. 137, no. 6, pp. 1403–1419, 1997. View at Publisher · View at Google Scholar · View at Scopus
  204. B. Ozdamar, R. Bose, M. Barrios-Rodiles, H. R. Wang, Y. Zhang, and J. L. Wrana, “Regulation of the polarity protein Par6 by TGFβ receptors controls epithelial cell plasticity,” Science, vol. 307, no. 5715, pp. 1603–1609, 2005. View at Publisher · View at Google Scholar · View at Scopus
  205. M. Oft, R. J. Akhurst, and A. Balmain, “Metastasis is driven by sequential elevation of H-ras and Smad2 levels,” Nature Cell Biology, vol. 4, no. 7, pp. 487–494, 2002. View at Google Scholar · View at Scopus
  206. E. Janda, K. Lehmann, I. Killisch et al., “Ras and TGFβ cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways,” Journal of Cell Biology, vol. 156, no. 2, pp. 299–313, 2002. View at Publisher · View at Google Scholar · View at Scopus
  207. J. Gotzmann, H. Huber, C. Thallinger et al., “Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-β1 and Ha-Ras: steps towards invasiveness,” Journal of Cell Science, vol. 115, no. 6, pp. 1189–1202, 2002. View at Google Scholar · View at Scopus
  208. L. Larue and A. Bellacosa, “Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways,” Oncogene, vol. 24, no. 50, pp. 7443–7454, 2005. View at Publisher · View at Google Scholar · View at Scopus
  209. J. Zavadil, M. Bitzer, D. Liang et al., “Genetic programs of epithelial cell plasticity directed by transforming growth factor-β,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6686–6691, 2001. View at Publisher · View at Google Scholar · View at Scopus
  210. L. Xie, B. K. Law, A. M. Chytil, K. A. Brown, M. E. Aakre, and H. L. Moses, “Activation of the Erk pathway is required for TGF-β1-induced EMT in vitro,” Neoplasia, vol. 6, no. 5, pp. 603–610, 2004. View at Publisher · View at Google Scholar · View at Scopus
  211. V. Ellenrieder, S. F. Hendler, W. Boeck et al., “Transforming growth factor β1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation,” Cancer Research, vol. 61, no. 10, pp. 4222–4228, 2001. View at Google Scholar · View at Scopus
  212. M. Grände, Å. Franzen, J.-O. Karlsson, L. E. Ericson, N.-E. Heldin, and M. Nilsson, “Transforming growth factor-β and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes,” Journal of Cell Science, vol. 115, no. 22, pp. 4227–4236, 2002. View at Publisher · View at Google Scholar · View at Scopus
  213. N. R. Christoffersen, A. Silahtaroglu, U. A. Ørom, S. Kauppinen, and A. H. Lund, “miR-200b mediates post-transcriptional repression of ZFHX1B,” RNA, vol. 13, no. 8, pp. 1172–1178, 2007. View at Publisher · View at Google Scholar · View at Scopus
  214. F. E. Ahmed, “Role of miRNA in carcinogenesis and biomarker selection: a methodological view,” Expert Review of Molecular Diagnostics, vol. 7, no. 5, pp. 569–603, 2007. View at Publisher · View at Google Scholar · View at Scopus
  215. M. Selbach, B. Schwanhäusser, N. Thierfelder, Z. Fang, R. Khanin, and N. Rajewsky, “Widespread changes in protein synthesis induced by microRNAs,” Nature, vol. 455, no. 7209, pp. 58–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  216. D. Baek, J. Villén, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel, “The impact of microRNAs on protein output,” Nature, vol. 455, no. 7209, pp. 64–71, 2008. View at Publisher · View at Google Scholar
  217. A. A. Burrow, L. E. Williams, L. C. T. Pierce, and Y. H. Wang, “Over half of breakpoints in gene pairs involved in cancer-specific recurrent translocations are mapped to human chromosomal fragile sites,” BMC Genomics, vol. 10, article no. 59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  218. L. Boominathan, “The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex,” PloS One, vol. 5, no. 5, Article ID e10615, 2010. View at Publisher · View at Google Scholar · View at Scopus
  219. J. Krützfeldt, N. Rajewsky, R. Braich et al., “Silencing of microRNAs in vivo with ‘antagomirs’,” Nature, vol. 438, no. 7068, pp. 685–689, 2005. View at Publisher · View at Google Scholar
  220. G. A. Calin, C. D. Dumitru, M. Shimizu et al., “Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15524–15529, 2002. View at Publisher · View at Google Scholar · View at Scopus
  221. M. V. Iorio, M. Ferracin, C. G. Liu et al., “MicroRNA gene expression deregulation in human breast cancer,” Cancer Research, vol. 65, no. 16, pp. 7065–7070, 2005. View at Publisher · View at Google Scholar · View at Scopus
  222. G. A. Calin, M. Ferracin, A. Cimmino et al., “A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia,” New England Journal of Medicine, vol. 353, no. 17, pp. 1793–1801, 2005. View at Publisher · View at Google Scholar
  223. G. A. Calin, C. Sevignani, C. D. Dumitru et al., “Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 9, pp. 2999–3004, 2004. View at Publisher · View at Google Scholar
  224. B. Qian, D. Katsaros, L. Lu et al., “High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-β1,” Breast Cancer Research and Treatment, vol. 117, no. 1, pp. 131–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  225. A. Schaefer, M. Jung, H. J. Mollenkopf et al., “Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma,” International Journal of Cancer, vol. 126, no. 5, pp. 1166–1176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  226. L. Jiang, P. Mao, L. Song et al., “miR-182 as a prognostic marker for glioma progression and patient survival,” American Journal of Pathology, vol. 177, no. 1, pp. 29–38, 2010. View at Publisher · View at Google Scholar
  227. Y. Zhang, M. Li, H. Wang et al., “Profiling of 95 MicroRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis,” World Journal of Surgery, vol. 33, no. 4, pp. 698–709, 2009. View at Publisher · View at Google Scholar · View at Scopus
  228. G. A. Calin and C. M. Croce, “MicroRNA signatures in human cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  229. A. Ventura and T. Jacks, “MicroRNAs and cancer: short RNAs go a long way,” Cell, vol. 136, no. 4, pp. 586–591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  230. P. A. Gregory, C. P. Bracken, A. G. Bert, and G. J. Goodall, “MicroRNAs as regulators of epithelial-mesenchymal transition,” Cell Cycle, vol. 7, no. 20, pp. 3112–3117, 2008. View at Google Scholar · View at Scopus
  231. C. P. Bracken, P. A. Gregory, N. Kolesnikoff et al., “A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition,” Cancer Research, vol. 68, no. 19, pp. 7846–7854, 2008. View at Publisher · View at Google Scholar · View at Scopus
  232. S. M. Park, A. B. Gaur, E. Lengyel, and M. E. Peter, “The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2,” Genes and Development, vol. 22, no. 7, pp. 894–907, 2008. View at Publisher · View at Google Scholar · View at Scopus
  233. S. Valastyan, F. Reinhardt, N. Benaich et al., “A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis,” Cell, vol. 137, no. 6, pp. 1032–1046, 2009. View at Publisher · View at Google Scholar · View at Scopus
  234. M. Korpal, E. S. Lee, G. Hu, and Y. Kang, “The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2,” Journal of Biological Chemistry, vol. 283, no. 22, pp. 14910–14914, 2008. View at Publisher · View at Google Scholar · View at Scopus
  235. J. Javor, S. Ferencik, M. Bucova et al., “Polymorphisms in the genes encoding TGF-β1, TNF-α, and IL-6 show association with type 1 diabetes mellitus in the Slovak population,” Archivum Immunologiae et Therapiae Experimentalis, vol. 58, no. 5, pp. 385–393, 2010. View at Publisher · View at Google Scholar · View at Scopus
  236. U. Burk, J. Schubert, U. Wellner et al., “A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells,” EMBO Reports, vol. 9, no. 6, pp. 582–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  237. J. Heino, R. A. Ignotz, M. E. Hemler, C. Crouse, and J. Massague, “Regulation of cell adhesion receptors by transforming growth factor-β. Concomitant regulation of integrins that share a common β1 subunit,” Journal of Biological Chemistry, vol. 264, no. 1, pp. 380–388, 1989. View at Google Scholar · View at Scopus
  238. A. Moustakas and C. H. Heldin, “Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression,” Cancer Science, vol. 98, no. 10, pp. 1512–1520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  239. N. Dumont, A. V. Bakin, and C. L. Arteaga, “Autocrine transforming growth factor-β signaling mediates Smad-independent motility in human cancer cells,” Journal of Biological Chemistry, vol. 278, no. 5, pp. 3275–3285, 2003. View at Publisher · View at Google Scholar · View at Scopus
  240. A. Tsapara, P. Luthert, J. Greenwood, C. S. Hill, K. Matter, and M. S. Balda, “The RhoA activator GEF-H1/Lfc is a transforming growth factor-β target gene and effector that regulates α-smooth muscle actin expression and cell migration,” Molecular Biology of the Cell, vol. 21, no. 6, pp. 860–870, 2010. View at Publisher · View at Google Scholar · View at Scopus
  241. W. Kong, H. Yang, L. He et al., “MicroRNA-155 is regulated by the transforming growth factor β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA,” Molecular and Cellular Biology, vol. 28, no. 22, pp. 6773–6784, 2008. View at Publisher · View at Google Scholar · View at Scopus
  242. N. Fils-Aimé, M. Dai, J. Guo, J. C. Neel, and J.-J. Lebrun, “Micro-RNA-584 and PHACTR1: new signaling route through which transforming growth factor-beta mediates the migration and actin dynamics of breast cancer cells,” The Journal of Biological Chemistry. In press.
  243. J. C. Neel and J.-J. Lebrun, “TGFβ/Activin A-induced miR-181 induces cellular migration and invasion in breast cancer cells,” Cellular Signalling. In press.
  244. E. Wiercinska, H. P. H. Naber, E. Pardali, G. Van Der Pluijm, H. Van Dam, and P. Ten Dijke, “The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system,” Breast Cancer Research and Treatment, vol. 128, no. 3, pp. 657–666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  245. G. Giannelli, E. Fransvea, F. Marinosci et al., “Transforming growth factor-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin,” American Journal of Pathology, vol. 161, no. 1, pp. 183–193, 2002. View at Google Scholar · View at Scopus
  246. G. Giannelli, S. Astigiano, S. Antonaci et al., “Role of the α3β1 and α6β4 integrins in tumor invasion,” Clinical and Experimental Metastasis, vol. 19, no. 3, pp. 217–223, 2002. View at Publisher · View at Google Scholar
  247. B. Wang, S. H. Hsu, S. Majumder et al., “TGFβ-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3,” Oncogene, vol. 29, no. 12, pp. 1787–1797, 2010. View at Publisher · View at Google Scholar · View at Scopus
  248. G. Han, S.-L. Lu, A. G. Li et al., “Distinct mechanisms of TGF-β1-mediated epithelial-to- mesenchymal transition and metastasis during skin carcinogenesis,” Journal of Clinical Investigation, vol. 115, no. 7, pp. 1714–1723, 2005. View at Publisher · View at Google Scholar
  249. Y. Wang, Y. Yu, A. Tsuyada et al., “Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM,” Oncogene, vol. 30, no. 12, pp. 1470–1480, 2011. View at Publisher · View at Google Scholar · View at Scopus
  250. M. Dai, A. A. Al-Odaini, A. Arakelian, S. A. Rabbani, S. Ali, and J.-J. Lebrun, “A novel function for p21Cip1 and acetyltransferase p/CAF as critical transcriptional regulators of TGFβ-mediated breast cancer cell migration and invasion,” Breast Cancer Research, vol. 14, no. 5, article no. R127, 2012. View at Publisher · View at Google Scholar
  251. A. AlOdaini, M. Dai, Y. Wang, S. Ali, and J.-J. Lebrun, “KiSS1 gene as a novel mediator of TGFβ pro-invasive effects in triple negative breast cancer,” In press.
  252. G. P. Gupta and J. Massagué, “Cancer metastasis: building a framework,” Cell, vol. 127, no. 4, pp. 679–695, 2006. View at Publisher · View at Google Scholar
  253. L. A. Kingsley, P. G. J. Fournier, J. M. Chirgwin, and T. A. Guise, “Molecular biology of bone metastasis,” Molecular Cancer Therapeutics, vol. 6, no. 10, pp. 2609–2617, 2007. View at Publisher · View at Google Scholar · View at Scopus
  254. J. J. Yin, K. Selander, J. M. Chirgwin et al., “TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development,” Journal of Clinical Investigation, vol. 103, no. 2, pp. 197–206, 1999. View at Google Scholar
  255. D. Javelaud, K. S. Mohammad, C. R. McKenna et al., “Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis,” Cancer Research, vol. 67, no. 5, pp. 2317–2324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  256. S. L. Kominsky, M. Doucet, K. Brady, and K. L. Weber, “TGF-β promotes the establishment of renal cell carcinoma bone metastasis,” Journal of Bone and Mineral Research, vol. 22, no. 1, pp. 37–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  257. E. Bertran, L. Caja, E. Navarro et al., “Role of CXCR4/SDF-1α in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-β,” Cellular Signalling, vol. 21, no. 11, pp. 1595–1606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  258. J. Wang, R. Loberg, and R. S. Taichman, “The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis,” Cancer and Metastasis Reviews, vol. 25, no. 4, pp. 573–587, 2006. View at Publisher · View at Google Scholar · View at Scopus
  259. N. Franchimont, S. Rydziel, and E. Canalis, “Transforming growth factor-β increases interleukin-6 transcripts in osteoblasts,” Bone, vol. 26, no. 3, pp. 249–253, 2000. View at Publisher · View at Google Scholar · View at Scopus
  260. S. M. Wahl, G. L. Costa, M. Corcoran, L. M. Wahl, and A. E. Berger, “Transforming growth factor-β mediates IL-1-dependent induction of IL-1 receptor antagonist,” Journal of Immunology, vol. 150, no. 8 I, pp. 3553–3560, 1993. View at Google Scholar · View at Scopus
  261. K. T. Steeve, P. Marc, T. Sandrine, H. Dominique, and F. Yannick, “IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology,” Cytokine and Growth Factor Reviews, vol. 15, no. 1, pp. 49–60, 2004. View at Publisher · View at Google Scholar · View at Scopus
  262. P. M. Siegel, W. Shu, R. D. Cardiff, W. J. Muller, and J. Massagué, “Transforming growth factor β signaling impairs neu-induced mammary tumorigenesis while promoting pulmonary metastasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8430–8435, 2003. View at Publisher · View at Google Scholar · View at Scopus
  263. D. Padua, X. H. F. Zhang, Q. Wang et al., “TGFβ primes breast tumors for lung metastasis seeding through angiopoietin-like4,” Cell, vol. 133, no. 1, pp. 66–77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  264. P. D. Bos, X. H.-F. Zhang, C. Nadal et al., “Genes that mediate breast cancer metastasis to the brain,” Nature, vol. 459, no. 7249, pp. 1005–1009, 2009. View at Publisher · View at Google Scholar
  265. A. V. Nguyen and J. W. Pollard, “Transforming growth factor β3 induces cell death during the first stage of mammary gland involution,” Development, vol. 127, no. 14, pp. 3107–3118, 2000. View at Google Scholar · View at Scopus
  266. M. Mieth, F. D. Boehmer, R. Ball, B. Groner, and R. Grosse, “Transforming growth factor-β inhibits lactogenic hormone induction of β-casein expression in HC11 mouse mammary epithelial cells,” Growth Factors, vol. 4, no. 1, pp. 9–15, 1990. View at Google Scholar · View at Scopus
  267. H. Rui, J.-J. Lebrun, R. A. Kirken, P. A. Kelly, and W. L. Farrar, “JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization,” Endocrinology, vol. 135, no. 4, pp. 1299–1306, 1994. View at Publisher · View at Google Scholar · View at Scopus
  268. H. Rui, R. A. Kirken, and W. L. Farrar, “Activation of receptor-associated tyrosine kinase JAK2 by prolactin,” Journal of Biological Chemistry, vol. 269, no. 7, pp. 5364–5368, 1994. View at Google Scholar · View at Scopus
  269. I. Dusanter-Fourt, O. Muller, A. Ziemiecki et al., “Identification of JAK protein tyrosine kinases as signaling molecules for prolactin. Functional analysis of prolactin receptor and prolactin—erythropoietin receptor chimera expressed in lymphoid cells,” EMBO Journal, vol. 13, no. 11, pp. 2583–2591, 1994. View at Google Scholar · View at Scopus
  270. J.-J. Lebrun, S. Ali, A. Ullrich, and P. A. Kelly, “Proline-rich sequence-mediated Jak2 association to the prolactin receptor is required but not sufficient for signal transduction,” Journal of Biological Chemistry, vol. 270, no. 18, pp. 10664–10670, 1995. View at Publisher · View at Google Scholar · View at Scopus
  271. J.-J. Lebrun, S. Ali, V. Goffin, A. Ullrich, and P. A. Kelly, “A single phosphotyrosine residue of the prolactin receptor is responsible for activation of gene transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 9, pp. 4031–4035, 1995. View at Google Scholar · View at Scopus
  272. J.-J. Lebrun, S. Ali, L. Sofer, A. Ullrich, and P. A. Kelly, “Prolactin-induced proliferation of nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2,” Journal of Biological Chemistry, vol. 269, no. 19, pp. 14021–14026, 1994. View at Google Scholar · View at Scopus
  273. S. Ali, Z. Chen, J.-J. Lebrun et al., “PTP1D is a positive regulator of the prolactin signal leading to β-casein promoter activation,” EMBO Journal, vol. 15, no. 1, pp. 135–142, 1996. View at Google Scholar · View at Scopus
  274. M. Schmitt-Ney, W. Doppler, R. K. Ball, and B. Groner, “β-Casein gene promoter activity is regulated by the hormone-mediated relief of transcriptional repression and a mammary-gland-specific nuclear factor,” Molecular and Cellular Biology, vol. 11, no. 7, pp. 3745–3755, 1991. View at Google Scholar · View at Scopus
  275. H. C. Kirch, B. Putzer, D. Brockmann, H. Esche, and O. Kloke, “Formation of the early-region-2 transcription-factor-1—retinoblastoma-protein (E2F-1-RB) transrepressor and release of the retinoblastoma protein from nuclear complexes containing cyclin A is induced by interferon α in U937V cells but not in interferon-α-resistant U937VR cells,” European Journal of Biochemistry, vol. 246, no. 3, pp. 736–744, 1997. View at Google Scholar · View at Scopus
  276. N. Chughtai, S. Schimchowitsch, J.-J. Lebrun, and S. Ali, “Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the β-casein gene promoter in mammary cells,” Journal of Biological Chemistry, vol. 277, no. 34, pp. 31107–31114, 2002. View at Publisher · View at Google Scholar · View at Scopus
  277. X. Liu, G. W. Robinson, K. U. Wagner, L. Garrett, A. Wynshaw-Boris, and L. Hennighausen, “Stat5a is mandatory for adult mammary gland development and lactogenesis,” Genes and Development, vol. 11, no. 2, pp. 179–186, 1997. View at Google Scholar · View at Scopus
  278. Z. Nouhi, N. Chughtai, S. Hartley, E. Cocolakis, J.-J. Lebrun, and S. Ali, “Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells,” Cancer Research, vol. 66, no. 3, pp. 1824–1832, 2006. View at Publisher · View at Google Scholar · View at Scopus
  279. C. W. Daniel, S. Robinson, and G. B. Silberstein, “The transforming growth factors beta in development and functional differentiation of the mouse mammary gland,” Advances in Experimental Medicine and Biology, vol. 501, pp. 61–70, 2001. View at Google Scholar · View at Scopus
  280. E. Faure, N. Heisterkamp, J. Groffen, and V. Kaartinen, “Differential expression of TGF-β isoforms during postlactational mammary gland involution,” Cell and Tissue Research, vol. 300, no. 1, pp. 89–95, 2000. View at Publisher · View at Google Scholar · View at Scopus
  281. R. Strange, F. Li, S. Saurer, A. Burkhardt, and R. R. Friis, “Apoptotic cell death and tissue remodelling during mouse mammary gland involution,” Development, vol. 115, no. 1, pp. 49–58, 1992. View at Google Scholar · View at Scopus
  282. S. D. Robinson, G. B. Silberstein, A. B. Roberts, K. C. Flanders, and C. W. Daniel, “Regulated expression and growth inhibitory effects of transforming growth factor-β isoforms in mouse mammary gland development,” Development, vol. 113, no. 3, pp. 867–878, 1991. View at Google Scholar · View at Scopus
  283. S. D. Robinson, A. B. Roberts, and C. W. Daniel, “TGFβ suppresses casein synthesis in mouse mammary explants and may play a role in controlling milk levels during pregnancy,” Journal of Cell Biology, vol. 120, no. 1, pp. 245–252, 1993. View at Publisher · View at Google Scholar · View at Scopus
  284. A. W. Sudlow, C. J. Wilde, and R. D. Burgoyne, “Transforming growth factor-β1 inhibits casein secretion from differentiating mammary-gland explants but not from lactating mammary cells,” Biochemical Journal, vol. 304, part 2, pp. 333–336, 1994. View at Google Scholar · View at Scopus
  285. C. Jhappan, A. G. Geiser, E. C. Kordon et al., “Targeting expression of a transforming growth factor β1 transgene to the pregnant mammary gland inhibits alveolar development and lactation,” EMBO Journal, vol. 12, no. 5, pp. 1835–1845, 1993. View at Google Scholar · View at Scopus
  286. D. F. Pierce, M. D. Johnson, Y. Matsui et al., “Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1,” Genes and Development, vol. 7, no. 12 A, pp. 2308–2317, 1993. View at Google Scholar · View at Scopus
  287. E. Cocolakis, M. Dai, L. Drevet et al., “Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation,” Journal of Biological Chemistry, vol. 283, no. 3, pp. 1293–1307, 2008. View at Publisher · View at Google Scholar · View at Scopus
  288. C. Grütter, T. Wilkinson, R. Turner et al., “A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 51, pp. 20251–20256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  289. A. Benigni, C. Zoja, D. Corna et al., “Add-on anti-TGF-β antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat,” Journal of the American Society of Nephrology, vol. 14, no. 7, pp. 1816–1824, 2003. View at Publisher · View at Google Scholar · View at Scopus
  290. S. Ananth, B. Knebelmann, W. Grüning et al., “Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell renal carcinoma,” Cancer Research, vol. 59, no. 9, pp. 2210–2216, 1999. View at Google Scholar · View at Scopus
  291. J. C. Morris, G. I. Shapiro, and A. R. Tan, “Phase I/II study of GC1008: a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC),” Journal of Clinical Oncology, vol. 26, supplement, abstract no. 9028, 2008. View at Google Scholar
  292. J. E. Thompson, T. J. Vaughan, A. J. Williams et al., “A fully human antibody neutralising biologically active human TGFβ2 for use in therapy,” Journal of Immunological Methods, vol. 227, no. 1-2, pp. 17–29, 1999. View at Publisher · View at Google Scholar
  293. A. L. Mead, T. T. L. Wong, M. F. Cordeiro, I. K. Anderson, and P. T. Khaw, “Evaluation of anti-TGF-β2 antibody as a new postoperative anti-scarring agent in glaucoma surgery,” Investigative Ophthalmology and Visual Science, vol. 44, no. 8, pp. 3394–3401, 2003. View at Publisher · View at Google Scholar · View at Scopus
  294. C. Hill, A. Flyvbjerg, R. Rasch, M. Bak, and A. Logan, “Transforming growth factor-β2 antibody attenuates fibrosis in the experimental diabetic rat kidney,” Journal of Endocrinology, vol. 170, no. 3, pp. 647–651, 2001. View at Publisher · View at Google Scholar · View at Scopus
  295. C. P. Denton, P. A. Merkel, D. E. Furst et al., “Recombinant human anti-transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 323–333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  296. D. Bonafoux and W. C. Lee, “Strategies for TGF-β modulation: a review of recent patents,” Expert Opinion on Therapeutic Patents, vol. 19, no. 12, pp. 1759–1769, 2009. View at Publisher · View at Google Scholar · View at Scopus
  297. P. Khaw, F. Grehn, G. Holló et al., “A phase III study of subconjunctival human anti-transforming growth factor β2 monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy,” Ophthalmology, vol. 114, no. 10, pp. 1822–1830, 2007. View at Publisher · View at Google Scholar
  298. Cambridge Antibody Technology, website, 2010.
  299. J. R. Dasch, D. R. Pace, W. Waegell, D. Inenaga, and L. Ellingsworth, “Monoclonal antibodies recognizing transforming growth factor-β: bioactivity neutralization and transforming growth factor β2 affinity purification,” Journal of Immunology, vol. 142, no. 5, pp. 1536–1541, 1989. View at Google Scholar · View at Scopus
  300. C. L. Arteaga, S. D. Hurd, A. R. Winnier, M. D. Johnson, B. M. Fendly, and J. T. Forbes, “Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-β interactions in human breast cancer progression,” Journal of Clinical Investigation, vol. 92, no. 6, pp. 2569–2576, 1993. View at Google Scholar · View at Scopus
  301. Genzyme Corporation, “Genzyme Corporate Pipeline,” 2010, http://www.genzyme.com/research/pipeline/pipe_home.asp.
  302. M. Lahn, S. Kloeker, and B. S. Berry, “TGF-β inhibitors for the treatment of cancer,” Expert Opinion on Investigational Drugs, vol. 14, no. 6, pp. 629–641, 2005. View at Publisher · View at Google Scholar · View at Scopus
  303. M. A. Rowland-Goldsmith, H. Maruyama, T. Kusama, S. Ralli, and M. Korc, “Soluble type II transforming growth factor-β (TGF-β) receptor inhibits TGF-β signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation,” Clinical Cancer Research, vol. 7, no. 9, pp. 2931–2940, 2001. View at Google Scholar · View at Scopus
  304. M. A. Rowland-Goldsmith, H. Maruyama, K. Matsuda et al., “Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis,” Molecular Cancer Therapeutics, vol. 1, no. 3, pp. 161–167, 2002. View at Google Scholar · View at Scopus
  305. F. Lopez-Casillas, H. M. Payne, J. L. Andres, and J. Massague, “Betaglycan can act as a dual modulator of TGF-β access to signaling receptors: mapping of ligand binding and GAG attachment sites,” Journal of Cell Biology, vol. 124, no. 4, pp. 557–568, 1994. View at Google Scholar · View at Scopus
  306. W. A. Border, N. A. Noble, T. Yamamoto et al., “Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease,” Nature, vol. 360, no. 6402, pp. 361–364, 1992. View at Publisher · View at Google Scholar · View at Scopus
  307. S. Komesli, D. Vivien, and P. Dutartre, “Chimeric extracellular domain of type II transforming growth factor (TGF)-β receptor fused to the Fc region of human immunoglobulin as a TGF-β antagonist,” European Journal of Biochemistry, vol. 254, no. 3, pp. 505–513, 1998. View at Publisher · View at Google Scholar · View at Scopus
  308. Y.-A. Yang, O. Dukhanina, B. Tang et al., “Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects,” Journal of Clinical Investigation, vol. 109, no. 12, pp. 1607–1615, 2002. View at Publisher · View at Google Scholar
  309. N. Hermida, B. López, A. González et al., “A synthetic peptide from transforming growth factor-β1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats,” Cardiovascular Research, vol. 81, no. 3, pp. 601–609, 2009. View at Publisher · View at Google Scholar
  310. S. T. Crooke, “Molecular mechanisms of action of antisense drugs,” Biochimica et Biophysica Acta, vol. 1489, no. 1, pp. 31–43, 1999. View at Publisher · View at Google Scholar
  311. I. Tamm, B. Dörken, and G. Hartmann, “Antisense therapy in oncology: new hope for an old idea?” Lancet, vol. 358, no. 9280, pp. 489–497, 2001. View at Publisher · View at Google Scholar
  312. K. H. Schlingensiepen, “The TGF-beta1 antisense oligonucleotide AP, 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: preclinical studies,” Journal of Clinical Oncology, vol. 22, abstract no. 3132, 2004. View at Google Scholar
  313. D. Fischer, A. Bischof, T. Egger et al., “Simultaneous reversal of immunosuppression, inhibition of tumor growth and migration by the TGF-beta1 antisense oligonucleotide AP, 11014 in prostatic, colorectal and non-small cell lung cancer,” in Proceedings of the American Association for Cancer Research Meeting, vol. 46, abstract no. 592, 2005.
  314. G. Stauder, A. Bischof, T. Egger et al., “TGF-β2 suppression by the antisense oligonucleotide AP, 12009 as treatment for pancreatic cancer: preclinical efficacy data,” Journal of Clinical Oncology, vol. 22, supplement, abstract no. 4106, no. 14s, 2004. View at Google Scholar
  315. K. H. Schlingensiepen, R. Schlingensiepen, A. Steinbrecher et al., “Targeted tumor therapy with the TGF-β2 antisense compound AP 12009,” Cytokine and Growth Factor Reviews, vol. 17, no. 1-2, pp. 129–139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  316. P. Hau, P. Jachimczak, R. Schlingensiepen et al., “Inhibition of TGF-β2 with ap 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies,” Oligonucleotides, vol. 17, no. 2, pp. 201–212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  317. Antisense Pharma, 2010, http://www.antisense-pharma.com/products/f_products.htm.
  318. C. D. Yingling, “Dihydropyrrolopyrazoles as TGFβ receptor kinase inhibitors for cancer therapy,” in Proceedings of the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, abstract 318, 2004.
  319. E. Calvo-Aller, J. Baselga, S. Glatt et al., “First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase,” Journal of Clinical Oncology, vol. 26, supplement, abstract no. 14554, 2008. View at Google Scholar
  320. G. Subramanian, R. E. Schwarz, L. Higgins et al., “Targeting endogenous transforming growth factor β receptor signaling in Smad4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype,” Cancer Research, vol. 64, no. 15, pp. 5200–5211, 2004. View at Publisher · View at Google Scholar · View at Scopus
  321. S. B. Peng, L. Yan, X. Xia et al., “Kinetic characterization of novel pyrazole TGF-β receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition,” Biochemistry, vol. 44, no. 7, pp. 2293–2304, 2005. View at Publisher · View at Google Scholar · View at Scopus
  322. R. Ge, V. Rajeev, G. Subramanian et al., “Selective inhibitors of type I receptor kinase block cellular transforming growth factor-β signaling,” Biochemical Pharmacology, vol. 68, no. 1, pp. 41–50, 2004. View at Publisher · View at Google Scholar
  323. M. Uhl, S. Aulwurm, J. Wischhusen et al., “SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo,” Cancer Research, vol. 64, no. 21, pp. 7954–7961, 2004. View at Publisher · View at Google Scholar · View at Scopus
  324. T.-T. Tran, M. Uhl, Y. M. Jing et al., “Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model,” Neuro-Oncology, vol. 9, no. 3, pp. 259–270, 2007. View at Publisher · View at Google Scholar
  325. N. J. Laping, E. Grygielko, A. Mathur et al., “Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity: SB-431542,” Molecular Pharmacology, vol. 62, no. 1, pp. 58–64, 2002. View at Publisher · View at Google Scholar · View at Scopus
  326. B. Zhang, S. K. Halder, S. Zhang, and P. K. Datta, “Targeting transforming growth factor-β signaling in liver metastasis of colon cancer,” Cancer Letters, vol. 277, no. 1, pp. 114–120, 2009. View at Publisher · View at Google Scholar
  327. D. Melisi, S. Ishiyama, G. M. Sclabas et al., “LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis,” Molecular Cancer Therapeutics, vol. 7, no. 4, pp. 829–840, 2008. View at Publisher · View at Google Scholar · View at Scopus
  328. Y. Fukai, M. Fukuchi, N. Masuda et al., “Reduced expression of transforming growth factor-β receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma,” International Journal of Cancer, vol. 104, no. 2, pp. 161–166, 2003. View at Publisher · View at Google Scholar · View at Scopus
  329. A. Miyajima, T. Asano, K. Seta, T. Asano, N. Kakoi, and M. Hayakawa, “Loss of expression of transforming growth factor-beta receptor as a prognostic factor in patients with renal cell carcinoma,” Urology, vol. 61, no. 5, pp. 1072–1077, 2003. View at Publisher · View at Google Scholar · View at Scopus
  330. T. Watanabe, T. T. Wu, P. J. Catalano et al., “Molecular predictors of survival after adjuvant chemotherapy for colon cancer,” New England Journal of Medicine, vol. 344, no. 16, pp. 1196–1206, 2001. View at Publisher · View at Google Scholar · View at Scopus
  331. M. Tateishi, I. Kusaba, H. Masuda, T. Tanaka, T. Matsumata, and K. Sugimachi, “The progression of invasiveness regarding the role of transforming growth factor β receptor type II in gastric cancer,” European Journal of Surgical Oncology, vol. 26, no. 4, pp. 377–380, 2000. View at Publisher · View at Google Scholar
  332. A. N. Houghton and D. Polsky, “Focus on melanoma,” Cancer Cell, vol. 2, no. 4, pp. 275–278, 2002. View at Publisher · View at Google Scholar · View at Scopus
  333. L. Ramont, S. Pasco, W. Hornebeck, F. X. Maquart, and J. C. Monboisse, “Transforming growth factor-β1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system,” Experimental Cell Research, vol. 291, no. 1, pp. 1–10, 2003. View at Publisher · View at Google Scholar · View at Scopus
  334. L. Humbert and J.-J. Lebrun, “TGF-beta inhibits human cutaneous melanoma cell migration and invasion through regulation of the plasminogen activator system,” Cellular Signalling, vol. 25, no. 2, pp. 490–500, 2012. View at Publisher · View at Google Scholar